CD19 and systemic lupus erythematosus: A trial is currently underway for a new CD19/CD3/human serum albumin-targeting TCE in SLE, designed to direct T cells to eliminate B cells, including those with diminished or undetectable CD19 expression, as determined by immunohistochemistry [73,74].